Analysis of hundreds of single-cell genomes from Yellowstone National Park shows bacterial species are less cohesive than previously thought.

Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

Background The likelihood of HIV acquisition is increased following forced vaginal sex. This relates in part to epidemiological and behavioural factors; however, the biological effects of forced ...

And they found that, while researchers produce far more papers after starting to use AI and the quality of the language used went up, the publication rate of these papers has dropped. The researchers ...

Shares of Agios Pharmaceuticals AGIO tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease. The ...

Nov 19 (Reuters) - Agios Pharmaceuticals (AGIO.O), opens new tab said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

The S&P 500 Index ($SPX) (SPY) on Friday closed down -0.05%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.65%, and the Nasdaq 100 Index ($IUXX) (QQQ ...

This year, Big Pharma has been active on the M&A front in cell and gene therapy (CGT), with AbbVie setting down $2.1 billion for Capstan Therapeutics’ novel CAR T therapies, Eli Lilly dropping $1.3 ...

Intel's revival could ease US scrutiny on foreign rivals, say analysts Intel-Nvidia deal poses a longer-term threat to Asian chipmakers, they say TSMC shares finish down 1.6%, Samsung down 1% The ...